Alzheimer Drug Approval Leads FDA Advisor to Resign

Last week, we covered the controversial approval of the first Alzheimer’s drug in 20 years. Last year, the FDA advisory committee determined that there wasn’t enough support that the treatment is effective. According to a CNN Health article, one member of the committee has resigned in protest of the recent approval of Biogen’s experimental drug that costs $56k/year.

Dr. David Knopman, a Mayo Clinic neurologist and member of the Peripheral and Central Nervous System Drugs Advisor Committee told CNN, “I resigned from the PCNS committee because if I ever were asked to serve on a future panel, I wouldn't have wanted to be treated in the disrespectful way that the aducanumab external advisers were treated.”